Relationship between glucose homeostatic disorders and testosterone in adult Nigerian women with polycystic ovary syndrome
Keywords:Diabetes mellitus, PCOS, Testosterone, Impaired fasting glucose
Background: Polycystic ovary syndrome (PCOS) is associated with hyperandrogenemia which is hypothesized to induce glucose homeostastic disorders among women with the syndrome. This study was thereby set to investigate the status of glucose homeostatic disorders and their relationship with testosterone among women with PCOS in Port Harcourt, Nigeria.
Methods: This was a retrospective study of 224 women with PCOS who had visited a tertiary hospital in Nigeria over a 10-year period. The laboratory characteristics of these patients were evaluated. Records on age, fasting plasma glucose (FPG) and serum total testosterone (TT) were collected and analyzed using Shapiro-Wilk, descriptive, chi-square, Fisher’s exact, two-way analysis of variance, and Pearson’s tests. A p-value <0.05 was considered significant.
Results: Glucose homeostatic disorders were documented in 49.1% of the study population. Impaired fasting glucose (IFG) and diabetes mellitus (DM) was observed among 37.5% and 11.6% of the study population respectively. There was difference in the mean TT levels among those with normal FPG, IFG, and DM (P<0.001). Those with DM had higher TT levels (2.47 ± 0.83 nmol/l) than those with IFG (2.12 ± 0.63 nmol/l) and normal glucose homeostatic status (1.63 ± 0.47 nmol/l). TT correlated positively with FPG among the overall study population (r=0.465; p-value = < 0.001), among those with IFG (r = 0.591; p-value=0.004), and among those with DM (r=0.404; p-value =0.012).
Conclusions: Glucose homeostatic disorders are common among PCOS patients in our environment, especially among those with higher testosterone levels. This warrants screening of all PCOS patients for glucose disorders as part of their management strategies.
Stein IF, Leventhal ML. Amenorrhoea associated with bilateral polycystic ovaries. Am J Obstet Gynecol. 1935;29:181-91.
Lavie O. Benign disorders of the ovaries and oviducts. In: Alan HD, Lauren N, Ashley SR, editors. Current Obstetrics and Gynaecologic Diagnosis and Treatment. 11th ed. New York: Lange Medical Publication; 2013. pp. 661-70.
Moharaj S, Amod A. Polycystic ovary syndrome. J Endocrinol Metab S Afr. 2009;14(2):86-95.
Goodarz MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011; 7(4): 219-31.
Joe-Kechebelu NN, Mbamara SU, Ikechebelu JI. Familial trend in polycystic ovarian syndrome. Ann Afr Med. 2013;12(3):132-4.
Zawadic JK, Danif A. Diagnostic criteria for polycystic ovarian syndrome: towards a rational approach. In: Polycystic Ovary Syndrome, Dunaif A, Givens JR, Haseltine F (Eds.). Cambridge, England: Blackwell Science, 1992. pp. 377-84.
Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006; 91(11):4237-45.
Rotterdam, ESHRE/ASRM-Sponsored, PCOS, Consensus, Workshop, Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004; 81(1):19-25
Zore T, Joshi NV, Lizneva D, Azziz R. Polycystic Ovarian Syndrome: Long-Term Health Consequences. Sem Reproduct Med. 2017;35 (3):271-81.
Dunaif A. Insulin Resistance and the polycystic ovary syndrome: Mechanism and implication for pathogenesis. Endocrine Review. 1997;18(6):774- 800.
Espinos-Gomez JJ, Corcoy R, Calaf J. Prevalence and predictors of abnormal glucose metabolism in Mediterranean women with polycystic ovary syndrome. Gynecol Endocrinol. 2009;25(3):199-204.
Trinder P. Determination of blood glucose using the oxidase – peroxidase system with a non-carcinogenic chromogen. J Clin Pathol. 1969;22(2);158-61.
Ismail AA, Astley P, Cawood M, Short F, Wakelin K, Wheeler M. Testosterone assays: guidelines for the provision of a clinical chemistry service. Ann Clin Biochem.1986;23:135 - 45.
Standards of medical care in diabetes-2007. Diabetes Care. 2007;30(suppl 1):S4-41.
Yau TTL. Ng NYH, Cheung LP, Ma RCW. Polycystic ovary syndrome: a common reproductive syndrome with long-term metabolic consequences. Hong kong Med J. 2017;23(6):662-34.
Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352(12):1223-36.
Lerchmann E, Schwetze V, Giuliani A, Obermayer-pietsh B. Assessment of glucose metabolism in polycystic ovary syndrome: HBA1c or fasting glucose compared with the oral glucose tolerance test as a screening method. Hum Reprod. 2013;28(9): 2537-44.
Barcellos CR, Rocha MP, Hayashidi SA, Nery M, Marcondes JA. Prevalence of abnormalities of glucose metabolism in patients with polycystic ovary syndrome. Ara Bras Endocrinol Metabol. 2007;51 (4):601-5.
Ehrmann DA, Barnes RB, Rosen-field RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999;22(1):141-6.
Alikor CA, Emem-Chioma PC. Epidemiology of diabetes and impaired fasting glucose in a rural community of Nigerian Niger Delta region. Niger J Med. 2015;24(2);114-24.
Ejike CECC, Uka NK, Nwanchukwu SO. Diabetes and pre-diabetes in adult Nigerians: Prevalence, and correlations of blood glucose with measures of obesity. Afr J Biochem. 2015;9(3):55-60.
Lazaridou S, Dinas K, Tziomalos K. Prevalence, pathogenesis and management of prediabetes and type 2 diabetes mellitus in patients with polycystic ovary syndrome. Hormones. 2017;16(4):373-80.
Navarro G, Allard C, Xu W, Mauvais-Jarvis F. The role of androgens in metabolism, obesity, and diabetes in males and females. Obesity. 2015;23(4): 719-9.
Dumitrescu R, Mehedintu C, Briceag I, Purcarea VL, Hudita D. The polycystic ovary syndrome: An update on metabolic and hormonal mechanisms. J Med Life. 2015;8(2):142-5.